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Abstract.   We report a case of  a Familial Hypercholesterolaemic (FH) patient (FH1) and her family members. They are
Malaysian of  Indian origin with evidence of  consanguinity in the parents. We characterised the LDL receptor gene mutation
in FH1, her brother (S1) and their mother, P2. The father (P1) died of  coronary heart disease (CHD) in his early 40’s. Our
investigation reveals that FH1 and her family do not carry the two of  the major known Familial Defective ApoB mutations,
Arg3500Gln and Arg3531Cys. Sequencing analysis of the LDL receptor gene demonstrated that FH1 is homozygous for a G
to A substitution at nucleotide position 1618, which causes the amino acid to change from alanine to threonine at position
519 (A519T). Both the mother and the eldest brother (S1) of FH1 are heterozygous for the A519T mutation. The A519T
mutation had been previously reported in Western ethnicity of  the United Kingdom, German and Icelandic origin but this is
the first to be identified in the Asian region.
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INTRODUCTION
Mutations in the low-density lipoprotein (LDL) receptor gene
on chromosome 19 result in an autosomal dominant
disorder, familial hypercholesterolaemia (FH) (Brown et al.,
1986). This disorder of defective LDL clearance gives rise to
increased plasma cholesterol 2 to 5 times higher than normal
and an increased risk of premature coronary heart disease.
The genetic mutation in this inherited disease may occur in
one (heterozygous FH) or both (homozygous FH) LDL
receptor alleles with frequencies of about 1 in 500 and 1 in a
million respectively (Bertolini et al., 1992). Despite
conventional diet and drug therapy, most FH heterozygotes
acquire CHD by the age of 35 while FH homozygotes
normally die of myocardial infarction (MI) within their first 2
decades of life (Brown et al., 1986; Hobbs et al., 1990). Early
detection of such patients is therefore necessary in order to
delay the onset of clinical symptoms.
Familial defective apoB (FDB), another inherited disease
that causes hypercholesterolaemia and premature development
of CHD (Goldstein et al, 1983), is clinically indistinguishable
from FH. Genetically, it is caused by mutation(s) in the apo B-
100 gene, specifically in the 3’ end that is not present in the apo
B-48 gene. Two major mutations in the apo B gene have been
associated with FDB: i) Arg3500Gln (Gaffney et al., 1995);
and ii) Arg3531Cys (Pullinger et al., 1995) that can both be
detected by PCR assays of the genomic DNA. A variety of
different mutations in the LDL receptor gene that result in FH
have been characterized that include gross deletions, major
gene rearrangements, small deletions and point mutations.
A database of LDL receptor gene mutations (http://
www.ucl.ac.uk/fh/genebook.html) indicates that there are
over 600 different mutations characterized worldwide
demonstrating a high degree of allelic heterogeneity at this
locus (Varret et al., 1997). The majority of  the LDL receptor
mutations characterised are among the European, American
and Afrikaner populations. In this study, we attempted to
characterise the LDL receptor gene mutation(s) in a Malaysian
familial hypercholesterolaemic patient and her family
members.
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MATERIALS AND METHODS
Patient and family.   The Paediatrics Clinic at University
Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia
had identified and clinically diagnosed a homozygous FH
patient (FH1) based on (i) high total cholesterol (TC) level of
14.6 mmol/L, (ii) high plasma LDL level of 13.44 mmol/L,
(iii) the presence of tendon xanthomas on both knees and
elbows (iv) family history of coronary heart disease (CHD).
The patient, FH1 is a 20 year-old Malaysian female of Asian-
Indian origin who was 16 year-old at the time of diagnosis.
FH1 initially presented with a concern about small lumps on
both elbows and knees. These lumps were first
detected as small nodules when she was 10 years old and
grew bigger as she got older. Upon inspection, the lumps
appeared to be tendon xanthomas (Figure 1a). Apart from
her knees and elbows (Figure 1b), these xanthomas were also
present on her Achilles’ tendon on both legs (Figure1c). For
her initial treatment, she received cholestyramine and
atorvastatin that subsequently reduced her cholesterol level
down to 9.0 mmol/L over a six-month period. There was
evidence of consanguinity in the family whereby the mother
of FH1 (P2) was married to her uncle (P1). P1 died of CHD
in his early 40’s. P2 was also hypercholesterolaemic with total
cholesterol level of 7.1 mmol/L but did not have any
xanthomas. FH1 had a brother (S1), aged 18 who was also
hypercholesterolaemic with a total cholesterol level of 8.2
mmol/L. Her two other siblings, S2 and S3, aged 16 and 15
years old respectively, were normocholesterolaemic and did
not show any clinical symptoms of FH.
The purpose of  the study was explained to the patient’s
mother, members of the family and other volunteers.
Informed consent was obtained from all to use their DNA
samples for this study.
RNA isolation.   Peripheral blood mononuclear cells
(PBMN) were isolated from fresh whole blood using
Histopaque®-1077 (Sigma Chemicals Corporation Ltd)
according to the manufacturer’s instructions. Total cellular
RNA (tcRNA) was isolated from PBMN using the Acid
Guanidinium Thiocyanate Phenol Chloroform Extraction
method as initially described by Chomczynski and Sacchi,
1987.
FDB analysis.   Two different non-radioactive PCR reactions
were performed on genomic DNA to exclude Familial
Defective ApoB (FDB) as the cause for the clinical symptoms.
Two known apoB mutations, FDB Arg3500Gln and
Arg3531Cys were investigated by PCR-based methods as
previously described by Gaffney et al, 1995 and Pullinger et al,
1995 respectively.
RT-PCR amplification of  the cDNA for gene sequencing.
Total cellular RNA (tcRNA) was reverse-transcribed to cDNA
before the LDL-R cDNA could be PCR-amplified. Specific
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Figure 1.   Pictures of subcutaneous tendon xanthomas in FH1.
(a) A huge tendon xanthoma in the elbow. (b) Several xanthomas
found in the knees. (c) Xanthomas of the Archilles tendon
oligonucleotide primers were used to reverse transcribe LDL-
R mRNA in two separate tubes. Exons 1 to 9 were reversed
transcribed using primer RTa: 5’ GCG ACC ACG TTC CTC
AGG TTG GGG ATG AGG and exons 5 to 18, RTb: 5’
ACT TCC TGG AGA GAA ATG GAG GTG T). TcRNA
(1000ng) was made up to 10.2 µl with sterile distilled water in
a thin-walled 0.5 ml microcentrifuge tube. The tubes
containing RNA were heated at 70°C for 10 minutes. A
mastermix (MM1) containing 1X first strand buffer (50 mM
Tris-HCl pH 8.3 at 25°C, 75 mM KCl and 3 mM MgCl2), 0.1
M DTT and 10 mM dNTP mix was prepared. After heating
the RNA, the tubes were then quick-chilled in ice. RNasin (32
units) was added followed by 7 µl of the MM1 and 1 µl (1.25
µM) of the appropriate primer. Both the tubes were then
heated at 42°C for 2 minutes before 200 units (1 µl) of
SUPERSCRIPT™ II enzyme was added to the tube. The
incubation for the reaction was carried out at 42°C for 50
minutes.
The two sets of cDNA were then PCR amplified in three
overlapping segments using 3 sets of oligonucleotide primers:
PCR1 (5’primer-220 – 5’AAC GAG TTC CAG TGC CAA
GAC GGG AAA TGC ATC3’ and 3’primer-225 – 5’TTG
TAG CCA CCC TCC AGG TTC ACG CAG AGC TG3’);
PCR2 (5’primer-224 – 5’GGA CCC AAC AAG TTC AAG
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TGT CAC AGC GGC3’ and 3’primer-231 – 5’CCA TGG
CTC AGG GTG GTC CTC TCA CAC CAG TT3’); PCR3
(5’primer-184 – 5’AAA CCT ACT GTC CCC AGA GGA
TAT GG3’ and 3’primer-183 – 5’ GCA GGG GCG GGA
CTC CAG GCA GA3’).
PCR1, PCR2 and PCR3 amplify exons 2-8, 6-14 and 13-
18 respectively. The cDNA from tube RTa was used in PCR1
while that from tube RTb was used in both PCR2 and PCR3.
In a thin-walled PCR microcentrifuge Eppendorf tube, 5 µl
of cDNA was mixed with 44.5 µl of mastermix (MM2) which
contains 1X Fermentas PCR buffer (containing 20 mM
ammonium sulfate, 75 mM Tris-HCl pH 8.8 at 25°C and
0.1% Tween 20), 1 mM MgCl2, 200 µM dNTPs, 10% DMSO
and 0.5 µM of each 5’ and 3’ primers. Taq DNA Polymerase
(2.5 units) was added to each tube and the reaction mixture
was overlaid with two drops (40 µl) of light mineral oil. The
amplification was performed in an Eppendorf Thermocycler
and the PCR program was optimised as follows: 35 cycles of
94°C for 1 minute for initial denaturation, 65°C for 1 minute
for annealing of primers and 72°C for 3 minutes for extension
of primers. The initial heating was adjusted to 94°C for 3
minutes. The PCR product was then purified using a
QIAquick Gel Extraction Kit (Qiagen) following the
manufacturer’s instruction. After purification, DNA was
quantified using a GeneQuant spectrophotometer.
Sequencing the PCR product/DNA.   Sequencing of the
LDL receptor gene was carried out using an automated ABI
Prism Gene Sequencer (Model 377, Version 2.1.1) at AMCAL,
University of Malaya, Kuala Lumpur. Seven overlapping
fragments of the gene were sequenced using 3 forward (54, G
and 77B) and 4 reverse (55, Fn, Jn and 183) primers.  Primers
54 and 55 were used to sequence PCR1 product while primers
G, 77B and Fn for PCR2 product and primers Jn and 183 for
PCR3 product. The primer sequences are; 54: 5’ CCC CAG
CTG TGG GCC TGC GAC AA; G: 5’ CCT GAG GAA
CGT GGT CGC TCT; 77B: 5’ CTA CTC GCT GGT GAC
TGA; 55: 5’ CAT CCG AGC CAT CTT CGC AGT C; Fn: 5’
AGA CCA GTA GAT TCT ATT GCT G; Jn: 5’ GGA GGT
GTC GGG AAC AGG CCG GGT GG; 183: as above.
The sequenced fragments of LDL receptor  gene were
analyzed using Apple Macintosh SeqEd Software. Parallel
visual comparison of the sequencing chromatography profiles
was also made between FH1, P2, S1, a normal individual
(N3) and the published LDL receptor gene sequence.
Analysis of the Ava II (exon 13),  Msp I (exon 15 and 18)
and Nco I (exon 18) polymorphisms.   PCR amplification
of the LDL receptor gene from genomic DNA was carried
out using the following primers; SP78: 5’GTC ATC TTC
CTT GCT GCC TGT TTA G and SP79: 5’GTT TCC ACA
AGG AGG TTT CAA GGT T for exon 13; SP82 : 5’ GAA
GGG CCT GCA GGC ACG TGG CAC T and SP83: 5’
GTG TGG TGG CGG GCC CAG TCT TTA C for exon 15;
N1: 5’ CAA TCT TGT CGT TGA TGG and N2: 5’ CAAACG
ATG CAG ACT GGA GG for exon 18. The PCR product
was then digested with Ava II (exon 15), Msp I (exon 18),
Nco I and Msp I (exon 18) restriction endonuclease following
the manufacturer’s instruction (New England Biolabs). The
digested products were separated using 2% agarose mini-gel,
pre-stained with EtBr.
RESULTS
Identification of the LDL receptor gene mutation in FH1.
Two known Familial Defective ApoB mutations, Arg3500Gln
and Arg3531Cys were not found in any of the family
members (data not shown). Comparison of nucleotide
sequencing results of  the amplified RT-PCR product from
FH1 with that of the published sequence and normal
individual (N3) revealed a single base substitution at nucleotide
position 1618 of the gene (Figure 3). This base substitution
was found in the PCR2 product, sequenced with primer-G,
which revealed nucleotide sequence from the middle of exon
9 to the end of exon 12. The substitution is from Guanine
(G) to Adenine (A), resulting in a codon change from GCC
to ACC, and an amino change at position 519 from alanine to
threonine (A519T).
For FH1’s mother, P2, the sequence generated at codon
1618 was found to be 50% G and 50% A, indicating
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P1 P2 (30s)
S1 (18) FH1 (20) S2 (16) S3 (15)
Hinc II
BsmA I
Ava II
Msp I
Nco I
Msp I
Hinc II
BsmA I
Ava II
Msp I
Nco I
Msp I
[7.1]
[8.2] [14.0] [3.7] [3.9]
Female, FH homozygous
Male, FH heterozygous
Female, FH heterozygous
Male, Normal
Female, Normal
Index patient
Figure 2.   Family pedigrees of the index patient (FH1) and her
family members, showing the haplotypes derived from the BsmA
I site in exon 10, Hinc II in exon 12, Ava II in exon 13, Msp I in
exon 15, Nco I in exon 18 and Msp I in exon 18 polymorphisms.
The haplotype for P1 was predicted based on haplotypes ob-
served from FH1, P2, S1, S2 and S3. The information for BsmA
I and Hinc II were extracted from sequencing analysis. Also shown
are their age and total cholesterol levels.
(+) denotes the presence of a restriction site and (-) denotes the
absence of a restriction site. Numbers in brackets denote the age
of individuals in years. Numbers in square brackets denote total
cholesterol level measured in mmol/L.
80 AsPac J. Mol. Biol. Biotechnol., Vol. 11 (2), 2003 Mutations in LDL Receptor gene causing Familial Hypercholesterolaemia
DISCUSSION
In this study, uncultured PBMN were used as the source for
RNA. All subjects were shown not to carry the two known
FDB mutations, Arg3500Gln and Arg3531Cys. Comparison
of  the nucleotide sequencing results of  the amplified RT-
PCR product from FH1 with that of P2, S1, N3 and the
published sequences revealed the presence of a Guanine (G)
to Adenine (A) substitution at position 1618 of the LDL
receptor gene (Figures 3). This single base substitution
(G1618A), results in a codon change from GCC to ACC and
an amino acid change from Alanine (Ala) to Threonine (Thr)
at position 519 (A519T). The G1618A mutation lies at
heterozygosity for the mutation (Figure 3). The sequencing
profile of  this particular mutation site in FH1’s siblings, S1
when compared with the sequence in FH1 and P2 is shown
in Figure 3. Similar to P2, analysis of the sequence at
nucleotide position 1618 of the LDL receptor gene also
showed two peaks that were 50% G and 50% A.
The variation in sequence seen at nucleotide 1617 in these
subjects (C in FH1 and P2, but T>C in S1 and N3) is a
reflection of the relatively rare exon 11 Aci I polymorphism,
previously reported in the LDL receptor gene mutation
database (http://www.ucl.ac.uk/fh/genebook.html., see also
Heath and Humpries, 1999). Sequence inspection of  RT-PCR
products revealed the genotype of two further polymorphic
sites in these individuals: for BsmA I site (exon 10):
FH1 (-/-), P2 (-/-), S1 (-/-) and for Hinc II site (exon 12):
FH1 (-/-), P2 (+/-), S1 (+/-). The base sequence at nucleotide
1617 and 1618 and these two polymorphic sites in individual
family members indicates that FH1 is homozygous for A519T
mutation having inherited the same allele from both parents.
This conclusion was corroborated by investigating the
genotype of a number of polymorphic sites in genomic DNA
from family members by restriction analysis. Both FH1 and
P2 were homozygous for the following sites: Ava II, exon
13; Msp I, exon 15; Nco I, exon 18; Msp I, exon 18, whereas
siblings S1, S2 and S3 were all heterozygous for the Ava II
site. Taken together with the sequence data on the Aci I site
(Figure 3) this argues strongly that FH1 has inherited the
same LDL receptor alleles from both parents. The haplotype
of the mutant allele is summarized in Figure 2.
Normal (N3) FH1
P2 S1
 
GCC ACC
 
CCG
A
 
CCG
A
Figure 3.   Nucleotide sequence of the coding strand of normal and mutant fragments of the LDL receptor mRNA of the PCR2
products sequenced with primer-G for N3, FH1, P2 and S1. The point of interest of each sample is indicated by the box. The
nucleotide for N3 at position 1618 is G while that of FH1 sample is A. P2 and S1 chromatography profiles show twin-peak with 50%
G and 50% A.
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nucleotide position 23 in exon 11 of the gene, which is part
of the second, EGF precursor domain of the LDL receptor.
This domain is responsible for the acid-dependent
dissociation of lipoproteins from the LDL-receptor in the
endosome during receptor recycling to the membrane (Brown
and Goldstein, 1986).
The A519T mutation is a Class V mutation of FH.
Amino acid A519 lies in one of the YTWD repeat domains
that form the central part of the EGF precursor domain.
This residue is completely conserved amongst vertebrate LDL
receptor and VLDL/vitellogenin receptors, but not within
the corresponding YTWD domains of the related LRP family
receptors (Mehta et al., 1991; Webb et al., 1994; Herz et al.,
1988). The crystal structure of the EGF-YTWD domain of
LDL receptor has recently been solved and shows A519
positioned between ß-sheets 2 and 3 of blade 4 of the ß-
propellor structure of the YTWD (Jeon et al., 2001). Prediction
of the effect of the A519T mutation on the structure and
cycling of the receptor are unclear, but it can be postulated
that the mutant A519T LDL receptors can be synthesized,
they may be able to bind to LDL to form an LDL/LDL
receptor complex, and the complex may be internalised or
endocytosed into the cell. However, the mutation may lead
to failure of dissociation of lipoproteins from the receptors
in the acidic environment of the endosome, whereby the
receptor fails to release the ligand. Consequently, the receptors
are degraded within the cell without being recycled to the
membrane. The essential event for the receptor-cycling
therefore fails to take place. Alternatively, receptor structure
may be sufficiently disrupted for it to be degraded during the
secretory process so that it never reaches the cell surface. As a
result, the number of receptors on the membrane is reduced
and consequently, the ability to clear LDL from circulation is
also reduced. Subsequently, both plasma TC and LDL-C levels
increase and this will lead to atherosclerosis and finally CHD.
Sun et al., (1997) reported that a heterozygous FH with A519T
mutation when compared to normal, had 42% of the normal
LDL receptor activity and 47% of the LDL receptor protein in
lymphoblast. If there were no effect of genetic background,
one would predict that FH1, a homozygote for the A519T
mutation would have very little LDL receptor activity or
protein. However, treatment of FH1 with cholestyramine
and atorvastatin reduced the LDL–cholesterol levels to similar
extent to that achieved by combined statin/bile acid
sequestrant treatment of the A519T heterozygote patient
described by Sun et al., 1998. This once again demonstrates
the effectiveness of statin treatment in homozygous FH
patients.
Analysis of the gene sequence from the mother of FH1
(P2) showed that at nucleotide position 1618, there is a 50%
G and 50% A indicating that she is a heterozygous for the
G1618A mutation; with one normal allele and one mutated
allele. Therefore, it is predicted that whilst producing normal
number of LDL receptors, half of them are defective, unable
to be recycled to the surface and are degraded. This is consistent
with the fact that she is already hypercholesterolaemic in her
30’s (TC=7.1 mmol/L) because the LDL can only be cleared
at half  of  the normal rate. FH1’s father, P1, who died due to
coronary heart disease in his early 40’s, is suspected to be a
heterozygote for the A519T mutation. Therefore, FH1 must
have received defective alleles from each parent. Since there is
consanguinity in the family, the A519T mutation must be
carried through successive generations of  the family.
Further analysis of the nucleotide sequence from the
predicted heterozygous brother of FH1 (S1) with TC level of
8.2 mmol/L, also showed that at nucleotide position 1618
there is a 50% G and 50% A confirming that he is a
heterozygous for the A519T mutation. S1 must have received
a defective allele from one of  the parents. FH1’s two other
siblings, S2 and S3 were normocholesterolaemic with TC=3.7
mmol/L and 3.9 mmol/L respectively (Figure 2), could have
received normal alleles from both parents. Further
investigation by identifying the presence of this A519T
mutation in the rest of  the FH1’s siblings and distant family
members would be beneficial, as this would encourage early
prophylactic measures such as diet therapy before the onset
of  clinical symptoms that may lead to CHD. However, the
majority of the paternal family members are living in India,
hence the difficulty of obtaining blood samples for analysis.
According to the LDL receptor mutation database
http://www.ucl.ac.uk/fh/mutab.html, the A519T mutation
identified in FH1 has already been found in other Western
ethnicities (United Kingdom, German and Icelandic).
However, this is the first to be identified in an FH patient in
Malaysia as well as in the Southeast Asia region. The haplotype
deduced for this allele will allow assessment of its relationship
to European alleles described.
CONCLUSIONS
We have identified the mutation in the LDL receptor gene as
a single base substitution at position 1618 of the gene that
results in amino acid change from Alanine to Threonine. It is
postulated that the LDL receptors can be synthesized, they
can bind to LDL to form LDL/LDL receptor complex, and
the complex can be internalised into the cell. However, the
mutation may lead to failure of dissociation of lipoproteins
from the receptors in the endosome hence the receptors are
degraded without being recycled to the membrane. As a result,
the number of receptors on the membrane is reduced and
the ability to clear LDL from the circulation will also be reduced.
Consequently, both plasma TC and LDL-C levels increase
and this will lead to atherosclerosis and finally CHD.
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